Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Veranova Appoints Thomas Rohrer VP of Bioconjugation | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Veranova Appoints Thomas Rohrer VP of Bioconjugation

Thomas brings more than 40 years of experience with biological process development and clinical manufacturing.

Veranova, a global developer and manufacturer of specialty and complex active pharmaceutical ingredients (APIs) for the pharma and biopharma sectors, has appointed Thomas Rohrer as Vice President of Bioconjugation. This appointment follows a recently announced investment to establish cGMP bioconjugation capabilities at its Devens, MA site.

Thomas brings more than 40 years of experience and a comprehensive understanding of biological process development and clinical manufacturing, including 30 years of licensed biological manufacturing. Throughout his career, he has successfully delivered complex biological programs for both clinical and commercial applications, including mammalian, microbial, vaccine, and gene therapy drug substances.

He spent 16 years at Lonza, where he led teams across several locations and departments, including Biopharmaceutical Manufacturing, Antibody Drug Conjugation, Biochemical Technologies, Project Evaluation and Commercial Development. His industry experience also includes Director of Process Development at Human Genome Sciences (later acquired by GSK), Otsuka America Pharmaceutical, Guidepoint Global LLC, Gentz Biopharmaceutical Consulting LLC, and most recently as Senior Director of Bioconjugate Technology Support at Samsung Biologics.

“We are delighted to welcome Tom as our Vice President of Bioconjugation,” said Rohtash Kumar, Senior Vice President of Development Operations and Chief Technology Officer at Veranova. “His invaluable experience and thought leadership in biological manufacturing will be critical as we continue to build and grow our bioconjugation offering in Devens, providing a more comprehensive suite of services to partners developing Antibody Drug Conjugates and other bioconjugates.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics